Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat neuronal protein 3 (LRRN3)
- Target
- LRRN3
- Molecular classification
- Leucine-rich repeat transmembrane protein, Single-pass type I membrane protein, Immunoglobulin superfamily domain containing protein, Fibronectin type III domain containing protein
01
Overview
Leucine-rich repeat neuronal protein 3 (LRRN3) is a highly conserved, single-pass type I transmembrane protein comprising 708 amino acids, notable for its 12 leucine-rich repeats, immunoglobulin domain, and fibronectin type III domain. LRRN3 is predominantly expressed in the human brain (especially cerebral cortex, hippocampus, cerebellum), as well as in heart and testes, and is involved in positive regulation of synapse formation and neural circuit development. Its expression responds to mitogenic and metabolic cues (such as through the Ras–MAPK pathway), and it acts upstream of several neural developmental processes. LRRN3 has emerging utility as a gene-expression biomarker of exposure (notably smoking), cardiovascular disease prognosis, and cancer outcome prediction, but there are no established drug interactions or validated therapeutic roles.
- Other names
- LRRN3NLRR-3NLRR3FIGLER5Leucine rich repeat neuronal 3Neuronal leucine-rich repeat protein 3fibronectin type III, immunoglobulin and leucine rich repeat domains 5Nbla10363UNQ194/PRO220FLJ11129
02
Mechanism of action
Null
03
Biological functions
Positive regulation of synapse assemblyAxon guidance and neural circuit formationCellular signaling (potentiates MAPK signaling)Protein-protein interaction (via LRR domains)
04
Disease associations
Cancer (expression in neuroblastoma, uveal melanoma, pheochromocytoma, predictive value)Neurodevelopmental/psychiatric disease (autism spectrum disorder susceptibility)Cardiovascular disease (biomarker in myocardial infarction/heart failure)Other (Smoking biomarker in blood, potential role in metabolic and inflammatory response)
05
Biomarkers
Blood LRRN3 mRNA upregulation as a biomarker of cigarette smokingPeripheral blood LRRN3 downregulation following myocardial infarction linked to heart failure riskComponent of gene-expression signatures in certain cancers and drug response predictions (e.g., statins, uveal melanoma)
Beyond the preview
Go deeper on Leucine-rich repeat neuronal protein 3 (LRRN3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeat neuronal protein 3 (LRRN3).